Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $4818.0.

  • Aytu Biopharma's Other Working Capital Changes fell 9939.62% to $4818.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4818.0, marking a year-over-year increase of 10047.85%. This contributed to the annual value of $5078.0 for FY2025, which is 6312.24% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Other Working Capital Changes is $4818.0, which was down 9939.62% from -$484000.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Other Working Capital Changes ranged from a high of $8.0 million in Q2 2021 and a low of -$2.9 million during Q2 2025
  • Its 5-year average for Other Working Capital Changes is $219348.1, with a median of $658.5 in 2023.
  • In the last 5 years, Aytu Biopharma's Other Working Capital Changes surged by 47500000.0% in 2021 and then tumbled by 35010000.0% in 2024.
  • Aytu Biopharma's Other Working Capital Changes (Quarter) stood at $9502.0 in 2021, then plummeted by 98.95% to $100.0 in 2022, then surged by 515.0% to $615.0 in 2023, then soared by 129656.1% to $798000.0 in 2024, then tumbled by 99.4% to $4818.0 in 2025.
  • Its Other Working Capital Changes stands at $4818.0 for Q4 2025, versus -$484000.0 for Q3 2025 and -$2.9 million for Q2 2025.